NBRV News

When there's trouble in the markets, IPO investors can rely on unprofitable, early-stage health care companies. The IPO market ended its annual end-of-summer lull as three health care IPOs priced this week, and each traded up about 30% or more. Two priced above the proposed range and one priced below. ...read more

Nabriva Therapeutics, which is developing a novel antibiotic for bacterial pneumonia, raised $92 million by offering 9 million ADSs at $10.25, below the downwardly revised price of $10.50. The company originally planned to offer 6 million ADSs at $15 to $17. Insiders plan to buy $42 million on the IPO, compared to $60 million in the revised terms and $50 million originally. Nabriva...read more

Nabriva Therapeutics, which is developing a novel antibiotic for bacterial pneumonia, lowered the proposed offer price ahead of its upcoming IPO on Thursday. The Vienna, Austria-based company now plans to raise $95 million by offering 9.0 million ADSs at $10.50. The company had previously filed to offer 6.0 million ADSs at a range of $15 to $17. At the new price, Nabriva...read more

After three weeks without any deals, the US IPO market is back in session. Three health care companies are each set to raise about $100 million in the week ahead. Backed by Fidelity, medical device company Penumbra (PEN) boasts strong sales growth (+41% in the 1H15) and...read more